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Development of a chlamydia infection model for
evaluating costs and outcomes of health interventions
Entwicklung eines Chlamydien-Infektionsmodells zur Evaluierung von
Kosten und Nutzen von Gesundheitsinterventionen
Abstract
Introduction: Chlamydia is a very common bacterial sexual transmitted
infection (STI) among young adults. High numbers of asymptomatic
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cases hamper a timely treatment start, whereas the treatment itself is
Wendelin Schramm1efficient and cheap. Proactive screening can decrease this mismatch.
There aremanymodels which are able to evaluate and simulate different
screening options. 1 Heilbronn University, GECKO
Institute for Medicine,Most of them though are based on old or insufficient data, are not ac-
cessible for everybody, or are not designed in a user-friendly way. Informatics and Economics,
Heilbronn, GermanyAim:We want to determine the feasibility of developing an easy-to-use
chlamydia infection model, which can be easily updated to reflect
changes in medical knowledge.
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Methods: Starting with a literature review, we have set up a chlamydia
infection model. This model was refined with the help of STI experts.
Primary Care and Population
Health, London, UK
The model was implemented by using the programming language Java
(version 1.6). We validated the model using internal and external valid-
ation methods.
Results: The implementation of the model allows users to edit all
parameters. The model consists of two separate sub-models. One sub-
model simulates health effects of chlamydia for individuals, including
the different outcomes in males and females. The other sub-model
tracks the spreading of chlamydia within the computed cohort and re-
gards heterosexual as well as homosexual partnerships. Both sub-
models are independent of each other and therefore easily exchange-
able. The overall model can be kept up to date by either updating single
parameters of the model or exchanging a sub-model.
The model can be operated by graphical user interfaces to enable non-
health economists and non-modelling experts to work with this disease
model.
Discussion: We showed the feasibility of implementing an easy-to-use
chlamydia model. This study can be regarded as a step towards
developingmore user-friendly decision support tools in health economics
to assist decision makers in medicine.
Keywords:Chlamydia trachomatis, decision support techniques,models,
theoretical, models, economical, nonlinear dynamics
Zusammenfassung
Einleitung: Chlamydien sind unter jungen Erwachsenen eine verbreitete
bakterielle sexuell übertragbare Krankheit (STI). Aufgrund einer hohen
Anzahl an asymptomatischen Fällen ist es schwer die Behandlung
zeitnah zu beginnen, obwohl diese an sich effizient und günstig ist.
Proaktives Screening kann diese Diskrepanz verringern. Es gibt bereits
viele Krankheitsmodelle, die in der Lage sind, verschiedene Screening-
optionen gegeneinander abzuwägen.
Ein Großteil davon beruht jedoch auf veralteten Daten, ist nicht frei
verfügbar oder nicht leicht zu bedienen.
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Ziele:Wir wollen herausfinden, ob es möglich ist ein Chlamydien-Infek-
tionsmodell zu entwickeln, welches einfach zu bedienen ist und auf
leichte Art undWeise aktualisiert werden kann um auf Änderungen des
zugrunde liegenden medizinischen Wissens reagieren zu können.
Methodik:Wir haben, beginnend mit einer Durchsicht der bereits exis-
tierenden Literatur, eine neues Chlamydien-Infektionsmodell entworfen.
Zusammenmit klinischen STI Experten wurde dieser Entwurf verfeinert.
Das Modell wurde dann in der Programmiersprache Java (Version 1.6)
realisiert. Anschließend validierten wir dasModell mit Hilfe interner und
externer Validierungsmethoden.
Ergebnisse: Die finale Version des Models erlaubt es Benutzern, alle
Parameter anzupassen. Das Modell besteht aus zwei Submodellen.
Eines davon simuliert die Effekte, die eine Chlamydien-infektion auf
eine einzelne Person hat und berücksichtigt dabei unterschiedliche
Krankheitsverläufe für Männer und Frauen. Das andere Submodell
modelliert die Verbreitung von Chlamydien in der simulierten Kohorte
unter Berücksichtigung von hetero- und homosexuellen Partnerschaften.
Beide Submodelle sind weitestgehend unabhängig voneinander und
daher leicht auszutauschen. Dadurch kann das gesamteModell aktuell
gehalten werden, indem entweder einzelne Parameter aktualisiert
werden oder ein Submodell ausgetauscht wird.
DasModell wird mittels grafischen Benutzeroberflächen bedient. Diese
ermöglichen Nutzern, welche keine Gesundheitsökonomen oder Ge-
sundheitsmodellierer sind, mit dem Modell zu arbeiten.
Diskussion:Wir haben gezeigt, dass es möglich ist, ein Chlamydien-In-
fektionsmodell zu entwickeln, welches einfach zu bedienen ist. Diese
Arbeit kann als erster Schritt in Richtung weiterer nutzerfreundlicher
Modellierungssoftware angesehen werden, um Entscheidungsträger in
der Medizin und Gesundheitsökonomie zu unterstützen.
Schlüsselwörter: Chlamydia trachomatis, Entscheidungsunterstützung,




Chlamydia trachomatis causes chlamydia infections (CT),
themost common bacterial sexually transmitted infection
(STI) in the United Kingdom (UK). Young adults account
for more than 65% of all cases, but the infection can af-
fect sexually active people of any age. The majority of
cases (>50% inmen, >70% in women) are asymptomatic,
which is why the National Chlamydia Screening
Programme in the UK recommends proactive screening
for young adults. Different testing methods are in use,
including point of care testing which gives results right
away. Furthermore, there are also various highly effective
treatment alternatives available with Doxycyline and
Azithromycin being the most common ones [1].
If chlamydia is left untreated sequelae can emerge, af-
fecting the patients’ quality of life even years after the
chlamydia infection is cured. Symptoms and sequelae
differ between sexes as they primarily affect the genito-
urinary organs. Reactive arthritis and infertility can be a
consequence of a chlamydia infection. Furthermore
females might develop chronic pelvic pain and ectopic
pregnancy, whereasmale sequelae could be epididymitis
or prostatitis, both of which could become chronic [2],
[3].
Health economics
Chlamydia does not only decrease the health of an indi-
vidual, it also costsmoney to diagnose and treat patients.
As resources in the health sector are finite, it is advisable
to determine how to get the best value for money. Health
economic evaluations deal with exactly this kind of
question, comparing the health benefit of interventions
with the arising costs of these interventions.
To compare health effects between different people an
objective measure for the health of a patient is needed.
Quality Adjusted Life Years (QALY) are such a kind of
measure. They describe the Quality of Life (QoL) of a pa-
tient over time. For example, a person who lives 4 years
with a QoL of 50% has a QALY of 2 (equals 0.5 multiplied
by 4 years). QALYs are just one example for utilities which
can be used in health economics, other measurements
are also established [4]. Details about QoL assessment
are beyond the scope of this paper and can be found
elsewhere [5].
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The second component of health economic evaluations
are costs, which can take various forms, for example
direct and indirect costs. If we combine both QALYs and
costs we can calculate the cost-effectiveness of an inter-
vention. The equation for an Incremental Cost-Effective-
ness Ratio (ICER) to compare two alternative interventions
is shown in Equation 1 [6].
Equation 1: Calculation of Incremental cost-effectiveness
ratio, where Costsnew = Costs of new intervention;
Costsstandard = Costs of treatment as usual (TAU)/ control;
QALYnew = Total QALYs of new intervention; QALYstandard =
Total QALYs TAU/control
The ICER on its own is difficult to interpret. A negative
ICER, for example, can indicate either a decrease in costs
with an increase in QALYs or a decrease in QALYs and an
increase in costs. On the other hand, a positive ICER can
result from an increase in both costs and QALYs or a de-
crease in both, costs and QALYs. These examples show
that the ICER cannot be interpreted on its own but should
always be examined in the context of the direction of
change in costs and QALY.
Disease modelling
There are various possible screening and treatment
methods for chlamydia. Furthermore, the part of the
population which should be covered by treatment can
vary. As screening methods and uptake, as well as the
treatment method can be combined in various different
ways, a multitude of combinations emerges. Disease
modelling can be a useful tool to compare these in terms
of costs and QALYs.
There are many different ways to model diseases, one of
which is Markov modelling. Markov models consist of
health states, which are connected by transitions. Health
States are used to describe the progress of the disease.
These health states have to cover all aspects of the dis-
ease and their definitions must not overlap with each
other. As Markov models are deterministic models,
transitions describe pre-defined proportions of the cohort
which transit from their current health state to another
health state. Transitions only depend on the current state
and not on the history of states. This feature is called
Markov property, or memorylessness of a Markov model
[7].
Another way to use the structure of a Markov model is to
look at patients individually. Then the transitions are no
longer interpreted as proportions of the population of this
state which makes a transition, but as transition probab-
ility for an individual. The transition probability is only af-
fected by the attributes of a person and the state they
are currently in. As this modelling approach looks at indi-
vidual patients it is also called microsimulation [8].
We can refer to these individuals in the microsimulation
also as agents. Agents are entities, either living or static,
of the real world, which can interact with each other. If
they are used to simulate scenarios we also call this
agent-basedmodelling [9]. In agent-basedmodelling each
agent is described by a set of attributes, these attributes
can change due to events, which either involve one or
multiple agents.
Whereasmany chlamydiamodels exist, most of them are
set up in a way so that they can answer one specific
research question. This is only one out of many example
where research software cannot be reused due to a nar-
row field of application. Typically, these disease models
are complicated to use and therefore, only accessible to
modelling experts. There might be a need for disease
models which non-experts users can operate to gain initial
understanding of amodelling problem before these users
consult disease modellers. Especially in the vivid market
of chlamydia screening and treatment a generic model
could make a difference.
Aims
This study aims to examine the feasibility of developing
an easy to use chlamydia model. Our scoping of the liter-
ature has shown that there is no such model currently
available. To develop such a model it is necessary to de-
velop a new and highly detailed chlamydia model. As
complex models might hamper non-expert users from
using the model it will be examined whether it is possible
to hide the complexity of disease modelling behind
graphical user interfaces (GUIs). Nevertheless, the user
should be able to edit every parameter of the model, as
we know thatmedical knowledge changes fast. A different
input can also be used to fit the model into another set-
ting. We therefore aim to find the balance between edit-
ability and user-friendliness.
Methods
The model development was broken down into two main
questions:
• What is the natural progress of chlamydia infection
and how can this be altered by treatment?
• How does CT spread within a population?
The first question is answered using Markov microsimu-
lations. It is necessary to look at each sex separately due
to the different disease process and consequences of
chlamydia for males and females.
The second question deals with the transmission of
chlamydia within a population. This is influenced by the
existing partnerships in a population as well as screening
and treatment interventions. We use agent-basedmodel-
ling to simulate these processes which we call from here
on “social model”.
The entire model has been implemented using the pro-
gramming language Java (version 1.6) in the integrated
development environment (IDE) of Oracle Eclipse Mars
[10]. This guarantees full flexibility in setting up the
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models and no restrictions on model type. Furthermore,
Java enables the implementation of GUIs.
Both sub-models are set up in such a manner that no
direct communication between those sub-models is ne-
cessary. Instead, the sub-models communicate using a
connector module with well-defined interfaces. This archi-
tecture enables future researchers to replace one sub-
model by another completely different sub-model if it
implements the same interface.
Although both sub-models are mostly independent there
is some need for information exchange. A connector
module is used to forward important events from one
sub-model to another, using their interfaces.
Disease model development
A scoping of the literature was used to gain an overview
over the current state of CTmodelling. The search strategy
consisted of two main parts, one part to find articles re-
lated to chlamydia and another part to find disease
modelling papers. Each part consisted of various search
terms, which were combined using the “OR” operator.
Both parts were then combined using the “AND” operator.
We searched Medline, using the PubMed interface for
articles related to chlamydia modelling, published after
2000, to focus on the most recent models as we did not
plan to do a full systematic review. To be included in the
overview, the modelling study had to be freely accessible
and report different health states to describe the progress
of a chlamydia infection. We considered every article type
as long a sufficient level of detail was provided to under-
stand the functionality of the model.
The search retrieved approximately 1,500 articles, out
of which 71 were eligible for full text screening. From
those we identified 15 papers for inclusion in the over-
view. Using these articles, we extracted a duplicate free
set of all health states which were used in these articles
to describe the progression of [11], [12], [13], [14], [15],
[16], [17], [18], [19], [20], [21], [22], [23], [24], [25]. We
added “reactive arthritis” to these health states as it was
never used by any model, but mentioned by basic literat-
ure on chlamydia. Using these extracted states, we de-
veloped two chlamydia disease sub-models one for each
sex, as the disease symptoms differ between the sexes.
Further sex-specific sequelae models have been
introduced. The planned model structure was validated
with STI experts and their feedback was used to amend
the models.
The default time horizon was set to 10 years with a warm
up period of 1 year. Themodel uses a default cycle length
of one day. Default discount factors for effects and costs
were set to 3.0%. These parameters can be changed by
users to fit their purposes.
Discounted costs are summed up for each day over all
persons and all models. The costs for each health state
are added to the persons’ sum once the person entered
this health state. Utilities are accessed by using QoL. The
QoL over all sub-models of one person is combined by
using the main chlamydia value as a base value. If a
sequela is present this value will be decreased by a
decrement assigned for each sequela.
Development of a social model
Sexual contact networks describe how sexual partner-
ships build and dissolve within a population. As this pro-
cess is likely to be the similar for most STIs (except human
immunodeficiency virus), we did not limit our scoping
searches to chlamydia, but also looked at studies about
gonorrhoea and other STIs. Based on the sexual networks
of these publications we developed a dynamic sexual
contact network, which we then discussed and improved
in further expert interviews. Overall, four experts were
consulted in face-to-face interviews, which lasted
approximately one hour each. These experts were two
STI doctors, one policy makers in medicine and one aca-
demic with major experience in influencing policy de-
cisions. This model parametrised using data from the UK
National Survey of Sexual Attitudes and Lifestyles [26].
Besides sexual contacts, this part of the model focusses
on the actual interventions, which are examined by the
model. These were derived from National Chlamydia
Screening Programme guidelines and parametrised using
the target values of those guidelines [27].
Development of user interfaces
To match the user interface of the final tool with the re-
quirements of a possible user of the tool, we used agile
methods to develop the user interfaces. Firstly, we
gathered information, which input parameters future user
might want to edit most often and how they want to get
the results presented. Based on this, a first set of mock-
ups was developed. In further interviews, thesemock-ups
were refined until they matched with the expectations of
the users. These user interfaces were connected with the
connector module, which combined this information of
the disease sub-model and the social sub-model.
Results
Disease models
We developed a main chlamydia disease model for each
sex. The female sub-model is displayed in Figure 1; the
male sub-model is displayed in Figure 2. Circles represent
the different health states. Additionally, some features
of the health states are described by the following coding:
• Green: A person being in this state is infective and can
therefore transmit the disease
• Red: A person in this state knows about his/her
chlamydia infection
• Orange: A person being screened should receive a
positive chlamydia test result, if screened
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Figure 1: The female main chlamydia model
Green states are infectious states, persons in red states know about their infection, orange states signalise, that screened persons
will receive positive test results.
Figure 2: The male main chlamydia model
Green states are infectious states, persons in red states know about their infection, orange states signalise, that screened persons
will receive positive test results.
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A modelled person that should receive a positive test
result can get a negative result as the test sensitivity and
specifity will be applied before delivering the result. Two
different types of transitions are used in this model: Solid
lines are used wherever a transition could happen due
to the natural progress of the disease, or in other words
whenever the transition is initiated by the disease sub-
model. Dotted lines, on the other hand, are used when-
ever a transition is initiated by the social model.
The states “No Chlamydia”, “Latent Chlamydia”,
“Symptomatic Chlamydia”, “Asymptomatic and Unknown
Chlamydia”, and “Asymptomatic and Known Chlamydia”
are used in the male and the female model and connect-
ed in the same way. An uninfected individual can only
become infected through sexual contact with an infected
individual per the social model. They then enter the stage
“Latent Chlamydia” and afterwards will be either in the
state “Asymptomatic Chlamydia” or “Symptomatic
Chlamydia”. In both cases, a natural curation of the
disease is possible. We assume all symptomatic infected
individuals will seek treatment. Treatment success then
leads to curation. If asymptomatically infected individuals
are screened, either by chance or by partner notification,
theymay become aware of the disease and subsequently
start treatment.
Untreated female chlamydia, either asymptomatic or
symptomatic, will develop into “pelvic inflammatory
disease (PID)” if not cured spontaneously. PID has a
probability of developing into an abscess if left untreated.
If PID is treated, the female is “uninfected” and hence
susceptible for a new episode of chlamydia again. Other-
wise, the female might end up being in state “PID with
complications” for one day before ending up in the unin-
fected state again. “PID with complications” is a marker
state. The possibility of developing a sequela increases
by the each of episodes of “PID with complications”. Un-
treated male chlamydia might progress to either epidi-
dymitis or prostatitis, both of which could become
chronic. The probability of having a sequela increases
with each episode of chlamydia a male undergoes.
The sequelae are simulated in separate models (see
Figure 3 for females and Figure 4 for males).
Figure 3: The female sequelae included in the model
Figure 4: The male sequelae included in the model
In each cycle, a randomnumber is drawn for each person
and each of the sub-models. Based on this random
number and the transition matrices (see Table 1 and
Table 2) a transition into another state might or might
not occur. All values are daily transition probabilities.
If the referenced study used a different time interval, the
probability was recalculated using Equation 2:
Equation 2: Equation to recalculate transition
probabilities to a daily basis, where pnew = the newly cal-
culated daily transition probability; pold = the transition
probability mentioned in the resource; tnew = 1 day; told =
the time interval of the old transition probability (in days)
In some cases, only the average time in a health state
was known. In this instance, the probability was chosen
in such a manner that 50% of the population would have
left this particular state by that day, as shown in
Equation 3:
Equation 3: Calculating a daily transition probability, if
only a mean duration of stay in health stae is given,
where pnew = the newly calculated daily transition probab-
ility; told = the referenced mean duration
All transition probabilities are to be regarded as sugges-
tions based on sound references from the authors as
users can alter each probability if needed.
If a female had at least one episode of PID, she is under
risk for developing either of these sequelae: reactive
arthritis, chronic pelvic pain (CPP), infertility or having an
ectopic pregnancy. An ectopic pregnancy can only occur
if the woman is pregnant, after the ectopic pregnancy
she will be in the state “no ectopic pregnancy” again. In-
fertility and CPP are chronic conditions, whichmeans that
they are absorbing states and cannot be left. Reactive
arthritis shows up in occasional episodes with a duration
of 6 weeks [28], resulting in a transition probability of
1.63%. The probabilities for developing each of the
sequela are shown in Table 3.
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Table 1: Transition matrix of daily transition probabilities for the female chlamydia model
NC=No Chlamydia; LC=Latent Chlamydia; AUC=Asymptomatic and Unknown Chlamydia; AKC=Asymptomatic and Known Chlamydia;
SC=Symptomatic Chlamydia; PID=Pelvic Inflammatory Disease; A=Abscess; PwC=PID with Complications
Table 2: Transition matrix of daily transition probabilities for the male Chlamydia model
NC=No Chlamydia; LC=Latent Chlamydia; AUC=Asymptomatic and Unknown Chlamydia; AKC=Asymptomatic and Known Chlamydia;
SC=Symptomatic Chlamydia; E=Epididymitis; P=Prostatitis
Table 3: Transition probabilities of developing a certain sequela
Each column contains the probability after the first/second/third
episode of Chlamydia (for males) or PID with complication (for
females). F=applicable for females; M=applicable for males;
CPP=Chronic Pelvic Pain; TI=Tubal Infertility; EP=Ectopic
Pregnancy; RA=Reactive Arthritis; CE=Chronic Epididymitis;
CP=Chronic Prostatitis; MI=Male Infertility.
The male sub-model for reactive as well as the transition
probabilities are the same as in equivalent femalemodel.
The three other sequela chronically manifest, which is
realised by final states. The transition probabilities are
shown in Table 3.
Default costs and utilities were assigned to each health
state (see Table 4), which can be edited by users. Costs
values were inflation-adjusted to represent the value of
2016. Costs in foreign currency were transformed into
pounds using the exchange rate of the publication date.
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Table 4: Costs and QoL values used in the model
Abbreviations see Tables 1, 2, and 3
Social model
Our model uses an open cohort; individuals can leave
the cohort and new individuals can enter it. Modelled
persons die in line with the UK death table [29]. If a per-
son surpasses the upper age border the model checks
whether they still have an active relationship. If not, the
person is removed from the model. If they have at least
one current partner the partnership is kept in the model
until the relationship ends or both partners exceed the
age limit. Individuals above the upper age limit will not
start new relationships. For each individual that dies, a
new individual of the same sex enters the model. This
can be either an uninfected person at the lower age bor-
der (growing up) or a person with any age of themodelled
interval and a randomhealth state (migration). This keeps
themodelled population at the same size throughout the
whole modelled time.
The social model is best described by looking at the dif-
ferent processes which are simulated. Processes are in-
fluenced by attributes of individuals which are randomly
assigned to each individual when they enter the sim-
ulation. Some of those, e.g. age, change over time,
whereas others, e.g. sex, will stay the same. The whole
model is parametrised for a UK context. Nevertheless, a
user can fit the parameters for any other given context.
Partnership building
To build a partnership, two random individuals are picked
out of the cohort. The model checks whether the param-
eters of both modelled persons match. Therefore it is
checked whether at least one of the potential partners
has reached his or hermaximumnumber of partnerships,
whether their sexual preferences match, whether their
sexual activity groups match, and whether their age
preference match. If all checks are passed, and neither
is already in a long-term relationship, they will start a long-
term relationship. Otherwise they start a short-term rela-
tionship.
Each of the previous checks examine one attribute of the
individuals. Persons have a preferred number of partner-
ships and a maximum number of partnerships, which is
looked at in the first check. The “sexual preference” de-
termines whether this person will prefer relationship with
amale or female or has no preference. The sexual activity
group is a value which describes how often this person
would like to have sex, this value is at 0.7 per day for the
highest group, 0.4 for the middle group and 0.2 for the
lowest group [30]. A mixing pattern (see Table 5) is ap-
plied to allowmixing between the different sexual activity
groups.
Table 5: Mixing matrix for sexual activity groups [31]
Each individual also has a preferred age difference for a
potential partner. Males tend to search for slightly
younger partners, whereas female are looking for slightly
older partners [26]. The confidence intervals around these
parameters increase over time.
This partnership building process is started a couple of
times each day to keep up the partnership building pro-
cess. A person can have one long partnership and even-
tually short partnerships concurrently. Based on the
preferences of the duration of a partnership and whether
the partnership is going to be a short or long, its length
is calculated.
Sexual intercourse
Based on the sexual activity groups of both partners the
average frequency of sexual intercourse is calculated.
For each day and each couple, a randomnumber is drawn
8/12GMS Medizinische Informatik, Biometrie und Epidemiologie 2017, Vol. 13(1), ISSN 1860-9171
Sailer et al.: Development of a chlamydia infection model for evaluating ...
to see whether they have sex at this particular day. Based
on their condomuse preferences and the condomsecurity
the probability of infection or a pregnancy is calculated.
Screening
Screening can either happen as a screening offer is made
for a randommodelled person or due to partner notifica-
tion, as the partner is found to be positive for CT earlier
on. Individuals can decline the screening offer. The test
result is influenced by infection status and the specifity
and sensitivity of the test.
Treatment
Modelled people who know about their chlamydia in-
fection will receive an offer to get treated. This offer is
declined by a certain percentage. Based on adherence,
efficacy data for treatment success is calculated. In any
case a rescreening is offered.
Validation
As themodel was built based on other publishedmodels,
its structure is comparable to already existing models.
Nevertheless, the structure of thisMarkovmodel contains
more health states than any other model we have found
during the scoping of the literature.
We conducted a one-way sensitivity analysis, changing
each input parameter by plus/minus 90%, 10%, and
2.5%. This analysis examined the effect (among others)
on the cost-effectiveness and the total number of in-
fections. The parameters that had the largest impact in
the model were “condom use” and “condom security”.
Furthermore, changes in the gender proportion as well
as a different mixingmatrix for sexual activity have a high
impact on the overall cost-effectiveness.
Changes in the initial distribution over the health states
did not change the results, as a warm-up is performed
before themodel starts evaluation. Other parameters like
the mortality table had little to no effect on the overall
result.
We could see a higher prevalence of chlamydia in our
models than we expected it to be in comparison to real
world data.
As the validation part of the software is encapsulated in
a module, it can easily be replaced by another validation
module. In this version, we only deployed a module for
deterministic one-way sensitivity analyses. However, it is
possible to enhance the internal validation by replacing
this module with another more sophisticated one, e.g.
for probabilistic sensitivity analyses.
User interaction
To keep the modelling tool as simple as possible but still
allow every parameter to be editable, we put all param-
eters in two categories. This was based on the results or
our expert interviews.
The first category includes parameters that users might
want to change regularly. Those can be changed using
the input mask shown in Figure 5. This mask is preloaded
with some default values, suggested by the authors.
Parameters, which could be changed on the GUI mostly
dealt with the screening and treatment process, as shown
in this list:
• Cohort demographics,
• Screening uptake (male/female, age group),
• Number of test offered per year,
• Test and treatment parameters (sensitivity, specifity,
adherence, efficacy, testing duration, treatment dura-
tion), and
• Partner notification per index case.
The second set contains parameters where users are
less likely to have additional information on or want to
change, e.g. transition probabilities for health state
changes. Parameters of the second set can be adapted
by changing their value in property files by using a text
editor.
After the modelling calculations are finished users can
examine the development of the prevalence for each
health state. The ICER, and the total number of infections
are reported. Figure 6 shows the result user interface
after a sample calculation.
Discussion
In this study, we present a new chlamydiamodel that can
be controlled by the user via GUIs. The model is available
from the authors upon request. We show that it can per-
form complex modelling calculations while providing a
graphical user interface. We demonstrate that it is pos-
sible to design a disease model in such a manner so that
it can be adapted to changes in medical knowledge,
hence increasing the potential field of usage and custom-
isability of the model. Nevertheless, the efficiency of the
proposedGUI has not been tested and other also effective
ways for building user interfaces exist. This situation was
not within the focus of this study, but it should be tested
in further research.
The validation has shown that the model is consistent
with current knowledge about chlamydia and chlamydia
modelling. We justify the higher prevalence in our model
with the absence of unknown cases.
The model is based on a multitude (n=159) of param-
eters, some of which are hard to find literature on and
therefore had to be estimated. As every parameter needs
a daily estimate due to the cycle length, the actual values
of the parameters can be hard to interpret. For example
the asymptomatic duration of chlamydia for women (on
average 365 days) translates into a rather cryptic daily
transition probability of 98.89% of staying in this health
state for the next cycle. The face validation of these
probabilities is not possible and non-modellers might be
objected by those.
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Figure 5: Input mask with the parameters users want to change most often
Figure 6: User interface to display all outcomes of interest of a calculation
The modelling tool is currently implemented in a compu-
tationally resource intensive way. This means that the
calculations take a long time to finish. The progress bar
showing the current state of the modelling process and
the display of the current prevalence of CT help the user
to wait for the results. Further projects though should try
to reduce calculation time so that the results can be ob-
tained in a shorter amount of time.
Future work
As the feasibility of hiding complex diseasemodels behind
GUIs was proven by this paper this work is currently being
continued. Subsequent research should focus on the
question whether these results are transferable to an
even more general approach. A first step would be to
develop a generic model which covers multiple STIs and
also examines interactions and coinfections of those.
It should be an aim to implement this kind of modelling
software in the workflows of policy makers in medicine.
The targeted dissemination of these results could ease
the life of decision makers.
Notes
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